Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Effect of Re-Treatment With Gefitinib ('Iressa', ZD1839) After Acquisition of Resistance
Detoxification Aid: Supports liver detoxification and helps remove toxins from the body
Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons
As with many other health trends that start on TikTok, microdosing is one that should be considered with a not-so-micro dose of skepticism.
Sci Rep (2019) 9(1):2902
US$ 24.23
US$ 28.76
US$ 20.44
US$ 28.55
